The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(4-(3-(cyclopropylamino)quinoxalin-2-yl)piperazin-1-yl)(4-(methylsulfonyl)phenyl)methanone 2,2,2-trifluoroacetic acid ID: ALA3716133
PubChem CID: 127024202
Max Phase: Preclinical
Molecular Formula: C25H26F3N5O5S
Molecular Weight: 451.55
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: CS(=O)(=O)c1ccc(C(=O)N2CCN(c3nc4ccccc4nc3NC3CC3)CC2)cc1.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C23H25N5O3S.C2HF3O2/c1-32(30,31)18-10-6-16(7-11-18)23(29)28-14-12-27(13-15-28)22-21(24-17-8-9-17)25-19-4-2-3-5-20(19)26-22;3-2(4,5)1(6)7/h2-7,10-11,17H,8-9,12-15H2,1H3,(H,24,25);(H,6,7)
Standard InChI Key: BNAOFHUQQRNIPS-UHFFFAOYSA-N
Molfile:
RDKit 2D
39 42 0 0 0 0 0 0 0 0999 V2000
7.6928 0.1427 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.3928 0.8927 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.3928 2.0927 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.3534 0.2930 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
8.7323 0.7424 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
8.7320 -0.4575 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
7.6928 -1.0573 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-14.0383 1.3229 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-12.9962 0.7279 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
-12.9909 -0.4721 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-7.8096 3.7478 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6111 0.7486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6111 -0.7486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2964 -1.4973 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.2964 1.4973 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 0.7486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 -0.7486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2964 -1.4973 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5929 -0.7486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5929 0.7486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2964 1.4973 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.9091 -1.5019 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.9086 1.5029 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.9097 3.0028 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.2093 3.7519 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.5078 3.0010 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-6.5067 1.5010 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.2071 0.7519 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-9.1077 2.9946 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.9067 -3.0027 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-10.4100 3.7391 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-11.7059 2.9837 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-11.6996 1.4837 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-10.3975 0.7391 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-9.1016 1.4945 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-7.8125 4.9478 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-14.0327 0.1231 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.6522 -4.2131 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.1522 -4.2076 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 1 0
2 4 2 0
1 5 1 0
1 6 1 0
1 7 1 0
9 8 2 0
10 9 2 0
12 13 2 0
13 14 1 0
14 17 2 0
16 15 2 0
15 12 1 0
16 17 1 0
17 18 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 16 1 0
13 22 1 0
12 23 1 0
23 24 1 0
23 28 1 0
24 25 1 0
25 26 1 0
26 27 1 0
27 28 1 0
26 11 1 0
11 29 1 0
22 30 1 0
29 31 2 0
31 32 1 0
32 33 2 0
33 34 1 0
34 35 2 0
35 29 1 0
11 36 2 0
33 9 1 0
9 37 1 0
38 30 1 0
39 38 1 0
30 39 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 451.55Molecular Weight (Monoisotopic): 451.1678AlogP: 2.57#Rotatable Bonds: 5Polar Surface Area: 95.50Molecular Species: NEUTRALHBA: 7HBD: 1#RO5 Violations: ┄HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 3.16CX LogP: 2.30CX LogD: 2.30Aromatic Rings: 3Heavy Atoms: 32QED Weighted: 0.64Np Likeness Score: -1.66
References 1. (2014) Quinoxaline derivatives as gpr6 modulators, 2. (2015) Quinoxaline derivatives as gpr6 modulators,